Effects Of Human Umbilical Cord Mesenchymal Stem Cells Therapy On The Immune Function And Prognosis In Patients With Hepatitis B Induced-decompensated Liver Cirrhosis

Objective To investigate the effect on the patient's immune function and prognosis of human umbilical cord mesenchymal stem cells(h UC-MSCs)therapy for the hepatitis B induced-decompensated liver cirrhosis.Methods 118 cases of patients with hepatitis B induced-decompensated liver cirrhosis were randomly divided into the control group(n=59)and the observation group(n=59).The two groups all received normal medical treatment,but the observation group also received h UCMSCs transplantation therapy.Around(4.0-4.5)×108 stem cells were transplanted by intervention(via proper hepatic artery).The levels of serum IL-6?TNF-??IL-10?TGF-?contents and the percentage of lymphocyte subsets in peripheral blood were determined both before and 1 week,4 weeks after treatment in the two groups.The MELD score and Child-Pugh score of 118 patients after treatment for 4,8,12,24,36 and 48 weeks were observed and recorded,and observe the liver failure and complications and survival during follow-up period in the two groups.Results After treatment for 1 week and 4 weeks,the levels of serum IL-6 and TNF-? in the observation group were significant lower than those in the control group(P<0.05 or P<0.001),but the levels of serum IL-10 and TGF-?in the observation group were significant higher than those in the control group(P<0.05 or P<0.001).After treatment for 1 week,the percentages of CD3+ CD4+T cell and CD4+CD25+Treg cell in the observation group were significantly higher than those in the control group(P < 0.001),but the percentages of CD3+ CD8+T cell and CD3-CD19+ B cell were significantly lower than those in the control group(P<0.05 or P<0.001).After treatment for 4 weeks,the percentages of CD3+ T cell,CD3+ CD4+T cell and CD4+ CD25+ Treg cell in the observation group were significantly higher than those in the control group(P<0.05 or P<0.001),but thepercentages of CD3+ CD8+T cell and CD3-CD19+ B cell wre significantly lower than those in the control group(P<0.05 or P<0.001).After treatment for 4,8,12 and 24 weeks,the MELD and the Child-Pugh score in the observation group were significantly lower than those in the control group(P<0.05).During the follow-up peried,none of the cases in the observation group developed liver failure,but 5 cases in the control group did.In addition,the rates of complications and mortality in the observation group were significantly lower than those in the control group(P<0.05).Conclusions The h UC-MSCs transplantation may alleviate liver inflammation and improve liver function,then may reduce the incidence of hepatic failure and mortality for patients with decompensated cirrhosis.